Please login to the form below

heart failure drug

This page shows the latest heart failure drug news and features for those working in and with pharma, biotech and healthcare.

Novartis hit by ‘COVID-19-related lockdowns’ in Q4

added. In the Q4 results, Novartis highlighted its main growth drivers – including its heart failure drug Entresto (sacubitril/valsartan), its immunology therapy Cosentyx (secukinumab) and its spinal muscular atrophy (SMA) gene

Latest news

Amgen, Cytokinetics’ heart failure drug disappoints in phase 3

A heart failure drug initially developed by Cytokinetics and taken into phase 3 development by Amgen and Servier has widely disappointed investors despite showing some statistically significant results. ... Also coming through the pipeline is Merck &Co
AZ’s Farxiga cuts risk of death in chronic kidney disease

AstraZeneca (AZ) has revealed some impressive results from a phase 3 study of its heart failure drug Farxiga in chronic kidney disease (CKD) at the European Society of Cardiology (ESC) virtual ... the risk of hospitalisation for heart failure and
Boehringer/Lilly's Jardiance hits the mark in pivotal heart failure trial

Boehringer Ingelheim and Eli Lilly’s heart failure drug Jardiance reduced the risk of cardiovascular death or hospitalisation due to heart failure in adult patients with and without diabetes – an important ... The EMPEROR-Reduced trial evaluated
Novartis stumbles in Q2 as COVID-19 impacts sales

Its psoriasis and arthritis drug Cosentyx (secukinumab) also saw a sales rise of 12% to $944m, while its heart failure drug Entresto (sacubitril/valsartan) climbed 40% to $508m. ... That includes its wet AMD drug Lucentis (ranibizumab), which fell 25% to
Merck, Bayer get FDA priority review for heart failure drug

Target action date set for January 2021. Merck and Bayer’s high-risk heart failure drug vericiguat has scored a priority review from the US Food and Drug Administration (FDA), four ... The New Drug Application (NDA) filed for vericiguat is aiming for

More from news
Approximately 0 fully matching, plus 76 partially matching documents found.

Latest Intelligence

Integrating patient reported outcomes into clinical trials

Drug developers have responded by putting PROs at the heart of their clinical trial designs. ... The performance of Novartis’ heart failure drug Entresto offers one example of that potential.
Heart failure therapy embarks on a new era

Ivabradine is thought to be the first drug to work by decreasing the heart rate as a consequence of its action on the If channel that controls the intrinsic pacemaker in ... In the 6, 500-patient SHIFT trial, for example, the drug showed a significant
Pharma deals during July 2013

Under this agreement, Servier has granted Amgen US rights to Procoralan (ivabradine), which is approved in Europe for chronic heart failure and stable angina in patients with elevated heart rates. ... Omecamtiv mecarbil is currently in phase II trials

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

Case Study: Qualitative research with payers in low and middle income countries

Our client wanted to understand in detail the usage decision drivers, triggers and processes for a high-cost innovative Acute Heart Failure (AHF) drug used in the acute emergency setting in

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Principal Medical Writer: Varies on experience

Account Management: Competitive Salary Offered

Senior Content Editor - Biotechnology: Salary TBC

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

PMHub

Add my company

Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?: The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.: Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....